Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
about
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTNonmyeloablative allogeneic hematopoietic cell transplantationChoice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published LiteraturePost-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyAdvances in the autologous and allogeneic transplantation strategies for multiple myelomaCurrent and emerging strategies for the prevention of graft-versus-host diseaseMilestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsIL-7 in allogeneic transplant: clinical promise and potential pitfallsLong-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine modelFludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialNonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita.Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease.Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialThe risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantationDonor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Aspergillus infections in transplant recipients.Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experienceOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allExpression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs.Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphomaHigh incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Allogeneic hematopoietic cell transplantation: the state of the artTreatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.A preclinical canine model for composite tissue transplantation
P2860
Q24685958-F733E81D-1856-487B-A295-06240C08041FQ26748780-698DCDA0-9170-4F62-8C59-44E5A8146102Q26749454-B679E57C-0304-496E-8932-29A907DBED80Q26852474-358BFB0D-E1C8-4AE8-9A31-EF36B8ACE683Q27010653-69EC0E99-CD75-430C-AADD-F6124EB41427Q27014801-B5601E8B-C54B-44FE-B597-368FD801FDAEQ27016541-C73E9ED8-9A34-48B7-ABCC-78BBF445ACDCQ28067102-2530FCEE-72BF-4A74-B228-CB0DB26BF180Q28259144-87B8413D-045D-4652-858F-A90E9B3BAD89Q30525173-A12E6587-CBA6-49CD-AD52-008A3E04D8DFQ30543777-8F023EAB-9BDB-4DF4-BA64-0CA423213FA7Q33346928-25E2EA15-379A-452F-9125-DD9DDD9E6AEAQ33360252-D2898F88-68A3-4B71-99C0-6F9893390859Q33360549-AD513471-AC5C-4955-9E86-4DB607B7697EQ33363625-569007B5-695A-4D6D-BCC2-F94E780E1EEAQ33386036-BF5E5160-CC74-48A7-82AA-E02E0FCDD8AEQ33396929-4A258FDF-EC5E-4964-89ED-35925F394F2DQ33560410-76145F34-F00C-4D66-940E-A221C1D15DAEQ33574209-3072DA63-447E-4704-9095-66C2F64DC895Q33653406-18D433A8-3965-43A7-A1E0-9D9D9997B96EQ33654676-ECE8501D-F31D-41CC-B525-8A9711E79D11Q33677489-7703E69A-0642-41E8-96C8-610662D95573Q33719294-A1B484A6-5B7E-42AB-B2B4-6AD276C2AEF7Q33763908-1BD75466-E1FA-4F31-A73C-D03B1F8DCFEEQ33771667-B36AD59C-6A1D-4239-AFAC-662A9C9A5F53Q33811417-3DE7D13C-4CFF-48AE-9E86-5D32FDD97E88Q33813439-A930089C-6E58-403F-9AE3-EE7C215AEBD3Q33838584-F746EB28-2A2F-49FE-A7B7-27E3D1B9DA7FQ33841438-BCDCE961-CB19-4C63-8210-82D103612BBDQ33886217-FBF0F516-5FC2-4484-B396-81198B875CFDQ33917170-D9B9BC08-695F-49B8-9EB0-A505DBEB0E85Q33930149-5867ED3D-829A-4CAC-B624-CA9B5281D1D0Q33933025-166D9D0A-8D35-4062-9F2C-B353928134E7Q33950015-2579A763-6EA7-42FE-9AFD-5FAD9F7D9C4DQ33978945-3D30A968-8E21-4C73-A83E-EA8C4D914C6FQ34111627-4060D6B2-3FED-4549-996D-A3BF388E1469Q34124707-7844F79D-F956-4100-B514-A6FE8EEFB3A1Q34145155-AAA6D371-71D7-4D4D-83DA-0632558BE389Q34197491-52C31DB4-700D-4A09-ACD6-3E66A8B9DBCCQ34286899-990941B7-31AB-4F04-8FD1-A4427F09C1C7
P2860
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Hematopoietic cell transplanta ...... th graft-versus-tumor effects.
@en
type
label
Hematopoietic cell transplanta ...... th graft-versus-tumor effects.
@en
prefLabel
Hematopoietic cell transplanta ...... th graft-versus-tumor effects.
@en
P2093
P1433
P1476
Hematopoietic cell transplanta ...... th graft-versus-tumor effects.
@en
P2093
A J Molina
B M Sandmaier
B Torok-Storb
D G Maloney
D Niederwieser
F C Grumet
G E Georges
P304
P356
10.1182/BLOOD.V97.11.3390
P407
P577
2001-06-01T00:00:00Z